Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic546 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Clinical trials
2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (268)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 |
| NCT05366569 | Bio-CAR-T BS Study | recruiting | — | 45 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04819854 | Single and Multiple Ascending Dose Study With EP395 | completed | Phase 1 | 78 | EpiEndo PharmaceuticalsINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07048535 | CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions | recruiting | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02315612 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | completed | Phase 1 | 134 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03178617 | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | active not recruiting | N/A | 214 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06735690 | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05550948 | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer | active not recruiting | N/A | 44 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06074666 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 | recruiting | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | recruiting | Phase 2 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05858593 | Positive Youth Development in the Metaverse | completed | N/A | 32 | University of GeorgiaOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL(PD1-VEN-CAG) | active not recruiting | Phase 3 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05519579 | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors | not yet recruiting | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04996160 | Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 2 | Tanja Andrea GruberOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05456698 | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | active not recruiting | Phase 2 | 31 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06892158 | Massage Impact on Sleep in Pediatric Oncology | recruiting | N/A | 70 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529223 | Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia.(ASTRA) | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05014165 | Backtracking Leukemia-Typical Somatic Mutations in Cord Blood | recruiting | — | 300 | Children's Oncology GroupNETWORK | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06956781 | Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)(MOST for PTSD) | recruiting | N/A | 200 | University of RochesterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04329325 | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07515430 | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | enrolling by invitation | — | 138 | Sun Yat-sen UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05972577 | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | completed | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05474170 | Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest | completed | N/A | 28 | Geneve TEAM AmbulancesOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509385 | The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07221656 | Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration | not yet recruiting | — | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04088890 | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | completed | Phase 1 | 52 | Matthew FrankOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06880913 | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials